Results 41 to 50 of about 611 (156)
Factors influencing feline antiparasitic prescriptions by veterinarians and demographics across parts of the UK. [PDF]
Abstract Background Antiparasitic drugs used in companion animals may persist in the environment, contributing to ecological contamination and raising One Health concerns. Understanding behavioural patterns of veterinarians’ prescription is essential for development of effective antiparasitic stewardship programmes. Methods A survey of 29 questions was
Hobbs RE, Duszak-Kowal A.
europepmc +2 more sources
Angiostrongylosis, caused by Angiostrongylus vasorum, is an important clinical disease in dogs in Europe with infection transmitted through infected snails and slugs which function as intermediate hosts. Previous studies demonstrated the preventive efficacy of a monthly administration of moxidectin in combination with sarolaner and pyrantel (Simparica ...
Lloyd, Anne +6 more
openaire +4 more sources
Background The safety and efficacy of a new spot-on formulation of selamectin plus sarolaner were evaluated for the treatment and control of natural flea infestations on cats in two non-randomised, multi-centre clinical trials conducted in 8 different ...
Raj Packianathan +4 more
doaj +1 more source
Functional Characterization of the Cat and Dog Wild-Type and Mutant MDR1 Carrier Proteins and Frequency of the MDR1 Gene Mutation in 800 Cats From Germany. [PDF]
ABSTRACT The ATP‐binding cassette transporter MDR1 P‐glycoprotein (syn. ABCB1) is an efflux carrier at the cell membrane that regulates drug absorption, distribution, and elimination. At the blood–brain barrier, MDR1 restricts brain entry of potentially neurotoxic drugs, such as ivermectin. In dogs and cats, MDR1 (syn.
Siegl L +6 more
europepmc +2 more sources
Abstract While many Bayesian state‐space models for infectious disease processes focus on population infection dynamics (eg, compartmental models), in this work we examine the evolution of infection processes and the complexities of the immune responses within the host using these techniques.
Felix M. Pabon‐Rodriguez +3 more
wiley +1 more source
Introduction This study aimed to determine the incidence of canine and feline tick paralysis cases presenting to two veterinary emergency hospitals before and after the introduction of new generation prophylactic acaricides. Methods This was a retrospective study, investigating the number of tick paralysis cases presenting to two emergency and critical
EM Ireland +3 more
wiley +1 more source
Biological variation of biochemical urine and serum analytes in healthy dogs
Abstract Background Biological variation (BV) of urinary (U) biochemical analytes has not been described in absolute terms, let alone as a ratio of the U‐creatinine or fractional excretion in healthy dogs. These analytes are potential diagnostic tools for different types of kidney damage and electrolyte disorders in dogs.
Anna K. Selin +5 more
wiley +1 more source
Canine and feline P‐glycoprotein deficiency: What we know and where we need to go
Abstract In 2001 the molecular genetic basis of so‐called “ivermectin sensitivity” in herding breed dogs was determined to be a P‐glycoprotein deficiency caused by a genetic variant of the MDR1 (ABCB1) gene often called “the MDR1 mutation.” We have learned a great deal about P‐glycoprotein's role in drug disposition since that discovery, namely that P ...
Katrina L. Mealey +2 more
wiley +1 more source
Abstract Afoxolaner, an insecticide and acaricide compound of the isoxazoline class, is available for dogs as an oral ectoparasiticide medicine (NexGard®) and as an oral endectoparasiticide medicine in combination with milbemycin oxime (MO), a macrocyclic lactone (NexGard® Spectra).
Marlene Drag +2 more
wiley +1 more source
New Insights Into Pathogenesis, Diagnostics, and Therapeutic Options for Canine Angiostrongylosis. [PDF]
ABSTRACT Objective To provide a comprehensive overview of Angiostrongylus vasorum infection in dogs, with a particular emphasis on recent developments in the understanding of disease pathophysiology and an update on developments in diagnostic and therapeutic options.
Elgueta I, Lewis D, Morgan ER, Helm J.
europepmc +2 more sources

